Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma

2006739 citationsJournal Article

Authors

Bart Barlogie · University of Arkansas for Medical Sciences

Guido Tricot · University of Arkansas for Medical Sciences

Elias Anaissie · University of Arkansas for Medical Sciences

John D. Shaughnessy · University of Arkansas for Medical Sciences

Erik Rasmussen · University of Washington

Frits van Rhee · University of Arkansas for Medical Sciences

Athanasios Fassas

Abstract

When incorporated into high-dose therapy for myeloma, thalidomide increased the frequency of complete responses and extended event-free survival at the expense of added adverse effects without improving overall survival. (ClinicalTrials.gov number, NCT00083551.).

Topics & Keywords

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Cancer therapeutics and mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 354, Issue 10, pp. 1021-1030

DOI: 10.1056/nejmoa053583

Field-Weighted Citation Impact: 43.70